Laurus Labs announced that it has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2-Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use
on COVID-19 patients in the country. Laurus Labs has already applied with CDSCO for emergency use authorization (EUA) for 2DG.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
